Stella Pharma (TSE:4888) EPS (Basic): 円-22.95 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4888 Stella Pharma Corp TSE:4888
74 GF Score
Price 円325.00
GF Value 円337.87
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Stella Pharma EPS (Basic)?

Stella Pharma TSE:4888 -0.31% 74 EPS (Basic) is 円-22.95 as of Mar. 2026. GuruFocus rates TSE:4888 with a GF Score™ of 74/100 and a GF Value™ of 円337.87 (Fairly Valued). The stock has 4 warning signs investors should review.

Stella Pharma's basic earnings per share (Basic EPS) for the six months ended in Mar. 2026 was 円-13.90. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-22.95.

Stella Pharma's EPS (Diluted) for the six months ended in Mar. 2026 was 円-13.90. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-22.95.

Stella Pharma's EPS without NRI for the six months ended in Mar. 2026 was 円-13.90. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -22.95.

During the past 3 years, the average EPS without NRI Growth Rate was 5.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Stella Pharma's highest 3-Year average EPS without NRI Growth Rate was 46.40% per year. The lowest was 4.30% per year. And the median was 8.30% per year.

Stella Pharma  (TSE:4888) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Stella Pharma EPS (Basic) Related Terms

Stella Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Stella Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stella Pharma EPS (Basic) Chart

Stella Pharma Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial -27.34 -26.97 -24.66 -4.22 -22.95

Stella Pharma Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.71 -8.21 3.99 -9.05 -13.90
TSE:4888
74GF Score
Stella Pharma Corp TSE:4888
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stella Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Stella Pharma's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-780.917-0)/34.024
=-22.95

Stella Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-473.002-0)/34.022
=-13.90

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-22.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円-22.95 mean?
Stella Pharma (TSE:4888) has a EPS (Basic) of 円-22.95 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Stella Pharma and its competitors.
Is Stella Pharma's EPS (Basic) too high?
Stella Pharma's current EPS (Basic) is 円-22.95. Overall, Stella Pharma has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's EPS (Basic) compare to VRTX and REGN?
Stella Pharma's EPS (Basic) of 円-22.95 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Stella Pharma and its competitors. Stella Pharma's current EPS (Basic) is 円-22.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円337.87, compared to a current price of 円325.00 — trading 3.8% below its estimated fair value. The current EPS (Basic) is 円-22.95. Stella Pharma's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current EPS (Basic) is 円-22.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stella Pharma (TSE:4888) Overvalued in 2026?

Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued. The current stock price of 円325.00 is trading 3.8% below its estimated GF Value™ of 円337.87. GuruFocus considers Stella Pharma to be Fairly Valued.

Key valuation signals for TSE:4888:

  • EPS (Basic): 円-22.95
  • GF Value™: 円337.87 vs. price of 円325.00 (3.8% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stella Pharma Business Description

Address 3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
74GF Score

Get the complete analysis for TSE:4888

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円325.00
Price
円337.87
GF Value